Market capitalization | $302.45m |
Enterprise Value | $361.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.64 |
P/S ratio (TTM) P/S ratio | 10.58 |
P/B ratio (TTM) P/B ratio | 5.42 |
Revenue growth (TTM) Revenue growth | -74.45% |
Revenue (TTM) Revenue | $28.59m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
13 Analysts have issued a uniQure N.V. forecast:
13 Analysts have issued a uniQure N.V. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 29 29 |
74%
74%
|
|
Gross Profit | -10 -10 |
111%
111%
|
|
EBITDA | -191 -191 |
55%
55%
|
EBIT (Operating Income) EBIT | -203 -203 |
53%
53%
|
Net Profit | -240 -240 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Head office | Netherlands |
CEO | Matt Kapusta |
Employees | 480 |
Founded | 2012 |
Website | www.uniqure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.